2017
Chapter 12 Dendritic Cell Therapy for Brain Tumors
Everson R, Antonios J, Tucker A, Liau L. Chapter 12 Dendritic Cell Therapy for Brain Tumors. 2017, 301-321. DOI: 10.1016/b978-0-12-802420-1.00012-0.Peer-Reviewed Original ResearchDC therapyDendritic cellsClinical trialsEvidence of immune responsesImmune responseLimitations of current treatment optionsTreatment of malignant gliomasDendritic cell therapyAntitumor immune responseAntigen presenting abilityCurrent treatment optionsDevelopment of alternative modalitiesDC vaccinesActive immunotherapyProlonged survivalMalignant gliomasPreclinical modelsTreatment optionsTumor cellsCell therapyClinical effectsVaccine formulationsBrain tumorsImmune systemBrain parenchyma
2016
IMST-56. TUMOR LYSATE-PULSED DC VACCINATION INDUCES NEOANTIGEN-SPECIFIC T CELL RESPONSES
Everson R, Shin N, Antonios J, Soto H, Tucker A, Zaretsky J, Orpilla J, Rathe S, Popescu F, Largaespada D, Liau L, Prins R. IMST-56. TUMOR LYSATE-PULSED DC VACCINATION INDUCES NEOANTIGEN-SPECIFIC T CELL RESPONSES. Neuro-Oncology 2016, 18: vi99-vi99. DOI: 10.1093/neuonc/now212.412.Peer-Reviewed Original ResearchAutologous tumor lysateTumor-infiltrating lymphocytesTumor-specific mutationsDC vaccinesDendritic cellsCD8+ T cell responsesEnhanced T cell infiltrationTumor-infiltrating lymphocyte culturesImmune responseIntracranial GL261 gliomasT cell infiltrationT cell responsesPhase III trialsTreatment groupsRelevant target antigensMurine glioma cell lineDC therapyTCR clonotypesTumor lysateGL261 gliomasIII trialsNeoantigen peptidesOriginal tumorGlioma cell linesLymphocytic infiltration